The impact of COVID-19 on health care-associated infections in intensive care units in low- and middle-income countries: International Nosocomial Infection Control Consortium (INICC) findings.

COVID-19 Coronavirus Developing countries Health care–associated infection Hospital infection INICC Infection control Infection prevention International Low- and middle-income countries Nosocomial infection Surveillance nosocomial infection control consortium

Journal

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
ISSN: 1878-3511
Titre abrégé: Int J Infect Dis
Pays: Canada
ID NLM: 9610933

Informations de publication

Date de publication:
May 2022
Historique:
received: 07 01 2022
revised: 16 02 2022
accepted: 18 02 2022
pubmed: 27 2 2022
medline: 29 4 2022
entrez: 26 2 2022
Statut: ppublish

Résumé

This study examines the impact of the COVID-19 pandemic on health care-associated infection (HAI) incidence in low- and middle-income countries (LMICs). Patients from 7 LMICs were followed up during hospital intensive care unit (ICU) stays from January 2019 to May 2020. HAI rates were calculated using the International Nosocomial Infection Control Consortium (INICC) Surveillance Online System applying the Centers for Disease Control and Prevention's National Healthcare Safety Network (CDC-NHSN) criteria. Pre-COVID-19 rates for 2019 were compared with COVID-19 era rates for 2020 for central line-associated bloodstream infections (CLABSIs), catheter-associated urinary tract infections (CAUTIs), ventilator-associated events (VAEs), mortality, and length of stay (LOS). A total of 7,775 patients were followed up for 49,506 bed days. The 2019 to 2020 rate comparisons were 2.54 and 4.73 CLABSIs per 1,000 central line days (risk ratio [RR] = 1.85, p = .0006), 9.71 and 12.58 VAEs per 1,000 mechanical ventilator days (RR = 1.29, p = .10), and 1.64 and 1.43 CAUTIs per 1,000 urinary catheter days (RR = 1.14; p = .69). Mortality rates were 15.2% and 23.2% for 2019 and 2020 (RR = 1.42; p < .0001), respectively. Mean LOS for 2019 and 2020 were 6.02 and 7.54 days (RR = 1.21, p < .0001), respectively. This study documents an increase in HAI rates in 7 LMICs during the first 5 months of the COVID-19 pandemic and highlights the need to reprioritize and return to conventional infection prevention practices.

Sections du résumé

BACKGROUND BACKGROUND
This study examines the impact of the COVID-19 pandemic on health care-associated infection (HAI) incidence in low- and middle-income countries (LMICs).
METHODS METHODS
Patients from 7 LMICs were followed up during hospital intensive care unit (ICU) stays from January 2019 to May 2020. HAI rates were calculated using the International Nosocomial Infection Control Consortium (INICC) Surveillance Online System applying the Centers for Disease Control and Prevention's National Healthcare Safety Network (CDC-NHSN) criteria. Pre-COVID-19 rates for 2019 were compared with COVID-19 era rates for 2020 for central line-associated bloodstream infections (CLABSIs), catheter-associated urinary tract infections (CAUTIs), ventilator-associated events (VAEs), mortality, and length of stay (LOS).
RESULTS RESULTS
A total of 7,775 patients were followed up for 49,506 bed days. The 2019 to 2020 rate comparisons were 2.54 and 4.73 CLABSIs per 1,000 central line days (risk ratio [RR] = 1.85, p = .0006), 9.71 and 12.58 VAEs per 1,000 mechanical ventilator days (RR = 1.29, p = .10), and 1.64 and 1.43 CAUTIs per 1,000 urinary catheter days (RR = 1.14; p = .69). Mortality rates were 15.2% and 23.2% for 2019 and 2020 (RR = 1.42; p < .0001), respectively. Mean LOS for 2019 and 2020 were 6.02 and 7.54 days (RR = 1.21, p < .0001), respectively.
DISCUSSION CONCLUSIONS
This study documents an increase in HAI rates in 7 LMICs during the first 5 months of the COVID-19 pandemic and highlights the need to reprioritize and return to conventional infection prevention practices.

Identifiants

pubmed: 35218928
pii: S1201-9712(22)00120-5
doi: 10.1016/j.ijid.2022.02.041
pmc: PMC8866162
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

83-88

Informations de copyright

Copyright © 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Références

Am J Infect Control. 2016 Jun 1;44(6):e81-90
pubmed: 26975716
Infect Control Hosp Epidemiol. 2022 Jan;43(1):26-31
pubmed: 33602361
Infect Control Hosp Epidemiol. 2012 Jul;33(7):704-10
pubmed: 22669232
Infect Control Hosp Epidemiol. 2022 Jan;43(1):32-39
pubmed: 33602380
Infect Control Hosp Epidemiol. 2021 Aug;42(8):997-1000
pubmed: 33213553
Infection. 2012 Aug;40(4):415-23
pubmed: 22371234
Infection. 2012 Oct;40(5):517-26
pubmed: 22711598
Crit Care. 2021 Jan 11;25(1):25
pubmed: 33430915
Am J Infect Control. 2008 Jun;36(5):309-32
pubmed: 18538699
Am J Infect Control. 2021 Jun;49(6):657-662
pubmed: 33775741
Am J Infect Control. 2020 Nov;48(11):1409-1411
pubmed: 32621857
Infect Control Hosp Epidemiol. 2013 Apr;34(4):415-23
pubmed: 23466916
Infect Control Hosp Epidemiol. 2010 Dec;31(12):1264-72
pubmed: 21029008
Infect Control Hosp Epidemiol. 2021 Jun 03;:1-5
pubmed: 34078507
Crit Care Med. 2012 Dec;40(12):3121-8
pubmed: 22975890
Infect Control Hosp Epidemiol. 2013 Jun;34(6):597-604
pubmed: 23651890
Am J Infect Control. 2021 Oct;49(10):1267-1274
pubmed: 33901588
Infect Control Hosp Epidemiol. 2013 Mar;34(3):229-37
pubmed: 23388356
Clin Microbiol Infect. 2021 Mar;27(3):451-457
pubmed: 33223114
Infect Control Hosp Epidemiol. 2012 Jul;33(7):696-703
pubmed: 22669231
Am J Infect Control. 1991 Feb;19(1):19-35
pubmed: 1850582
Infect Control Hosp Epidemiol. 2022 Jan;43(1):12-25
pubmed: 34473013
Am J Infect Control. 2008 Nov;36(9):e1-12
pubmed: 18992646
Infect Control Hosp Epidemiol. 2022 Jun;43(6):790-793
pubmed: 33719981

Auteurs

Victor D Rosenthal (VD)

Department of Public Health Sciences, University of Miami Miller School of Medicine, Miami, FL, USA; International Nosocomial Infection Control Consortium, Miami, FL, USA. Electronic address: victor_rosenthal@inicc.orgvic@inicc.org.

Sheila Nainan Myatra (SN)

Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, India.

Jigeeshu Vasishtha Divatia (JV)

Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, India.

Sanjay Biswas (S)

Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, India.

Anjana Shrivastava (A)

Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, India.

Majeda A Al-Ruzzieh (MA)

King Hussein Cancer Center, Amman, Jordan.

Omar Ayaad (O)

King Hussein Cancer Center, Amman, Jordan.

Ariungerel Bat-Erdene (A)

Intermed Hospital, Ulaanbaatar, Mongolia.

Ider Bat-Erdene (I)

Intermed Hospital, Ulaanbaatar, Mongolia.

Batsaikhan Narankhuu (B)

Intermed Hospital, Ulaanbaatar, Mongolia.

Debkishore Gupta (D)

BM Birla Heart Research Centre, Kolkata, India.

Subhranshu Mandal (S)

BM Birla Heart Research Centre, Kolkata, India.

Sankar Sengupta (S)

BM Birla Heart Research Centre, Kolkata, India.

Hala Joudi (H)

Hammoud Hospital University Medical Center, Saida, Lebanon.

Ibrahim Omeis (I)

Hammoud Hospital University Medical Center, Saida, Lebanon.

Hala Mounir Agha (HM)

Cairo University Specialized Pediatric Hospital, Cairo, Egypt.

Amr Fathallala (A)

Cairo University Specialized Pediatric Hospital, Cairo, Egypt.

El Hossein Mohahmed (EH)

Cairo University Specialized Pediatric Hospital, Cairo, Egypt.

Irem Yesiler (I)

Ankara University Faculty of Medicine, Ankara, Turkey.

Mehmet Oral (M)

Ankara University Faculty of Medicine, Ankara, Turkey.

Menekse Ozcelik (M)

Ankara University Faculty of Medicine, Ankara, Turkey.

Yatin Mehta (Y)

Medanta The Medicity, Gurgaon, India.

Smita Sarma (S)

Medanta The Medicity, Gurgaon, India.

Souranshu Chatterjee (S)

Medanta The Medicity, Gurgaon, India.

Souad Belkebir (S)

An Najah National University, Nablus, Palestine.

Alaa Kanaa (A)

An Najah National University Hospital, Nablus, Palestine.

Rawan Jeetawi (R)

An Najah National University Hospital, Nablus, Palestine.

Samantha A Mclaughlin (SA)

Department of Public Health Sciences, University of Miami Miller School of Medicine, Miami, FL, USA.

James M Shultz (JM)

Department of Public Health Sciences, University of Miami Miller School of Medicine, Miami, FL, USA.

Gonzalo Bearman (G)

Virginia Commonwealth University School of Medicine, Richmond, VA, USA.

Zhilin Jin (Z)

Department of Public Health Sciences, University of Miami Miller School of Medicine, Miami, FL, USA.

Ruijie Yin (R)

Department of Public Health Sciences, University of Miami Miller School of Medicine, Miami, FL, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH